CREON
ApprovedWithdrawn 3 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency (EPI)
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Trial Timeline
May 6, 2020 → Sep 22, 2021
NCT ID
NCT04315311About CREON
CREON is a approved stage product being developed by AbbVie for Exocrine Pancreatic Insufficiency (EPI). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04315311. Target conditions include Exocrine Pancreatic Insufficiency (EPI).
What happened to similar drugs?
2 of 3 similar drugs in Exocrine Pancreatic Insufficiency (EPI) were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05069597 | Approved | Completed |
| NCT04949828 | Pre-clinical | Completed |
| NCT04315311 | Approved | Withdrawn |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency (EPI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 29 |
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 40 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 35 |
| Pancrelipase + Placebo | AbbVie | Approved | 35 |
| Pancrelipase Capsules | AbbVie | Approved | 50 |
| Lipacreon | Viatris | Pre-clinical | 23 |